Supporting these results, the ROC analyses suggest that the accuracy of plasma p‐tau217 was similar to that found with CSF p‐tau217 or PET biomarkers and that the models were not improved when combining amyloid with the tau markers. This evidence concerns the gene MAPT and amyloidosis.